Severe Respiratory Disease Among Children With and Without Medical Complexity During the COVID-19 Pandemic

Christina Belza, PhD, MN; Eleanor Pullenayegum, PhD, Katherine E. Nelson, MD, PhD; et al ,JAMA Netw Open. 2023;6(11):e2343318. doi:10.1001/jamanetworkopen.2023.43318 Key Points Question  Did rates and outcomes of severe respiratory illness change during the first 2 years of the pandemic, compared with prepandemic, among children with medical complexity and those without medical complexity? Findings  In this repeated cross-sectional study of 139 078 respiratory hospitalizations in Canada, there were more […]

COVID-19 Lung Damage

Panagis Galiatsatos, M.D., M.H.S.  February 28, 2022  John’s Hopkins Like other respiratory illnesses, COVID-19 can cause lasting lung damage.  “As we continue to learn about COVID-19, we’re understanding more regarding how it affects the lungs during acute illness and afterward. And this is especially true with the virus’ ongoing variants, as well,” Galiatsatos says. What […]

Post-COVID Interstitial Lung Disease—The Tip of the Iceberg

Namrata Kewalramani, MD,a,b,∗ Kerri-Marie Heenan, MB Bch, BAO,c Denise McKeegan, MB Bch, BAO, MSc,c and Nazia Chaudhuri, MD, PhDd Immunol Allergy Clin North Am. 2023 May; 43(2): 389–410. Published online 2023 Mar3. doi: 10.1016/j.iac.2023.01.004 PMCID: PMC9982726PMID: 37055095 The proportion of symptomatic patients with post-coronavirus 2019 (COVID-19) condition (long COVID) represents a significant burden on the individual as well as on the health care systems. […]

Predictive Role of Biomarkers in COVID-19 Mortality

Ayşe Yılmaz,1 Öztürk Taşkın,1 Ufuk Demir,1 and Veysel G Soylu2 Cureus. 2023 Jan; 15(1): e34173. Published online 2023 Jan 24 doi: 10.7759/cureus.34173 PMCID: PMC9950690PMID: 36843833 Abstract Background The coronavirus disease 2019 (COVID-19) pandemic has resulted in high mortality among patients in critical intensive care units. Hence, identifying mortality markers in the follow-up and treatment of these patients is essential. This study aimed to evaluate […]

COVID-19 Lung Damage

Panagis Galiatsatos, M.D., M.H.S. February 28, 2022 Like other respiratory illnesses, COVID-19 can cause lasting lung damage. Panagis Galiatsatos, M.D., M.H.S., is an expert on lung disease at Johns Hopkins Bayview Medical Center and sees patients with COVID-19. He explains some of the short- and long-term lung problems brought on by the new coronavirus. “As […]

Doxycycline in the Coronavirus Disease 2019 Therapy

Karolina Dorobisz, 1 Tadeusz Dorobisz, 2 Dariusz Janczak, 2 and Tomasz Zatoński 1 Author information Article notes Copyright and License information PMC Disclaimer Ther Clin Risk Manag. 2021; 17: 1023–1026. Published online 2021 Sep 21. doi: 10.2147/TCRM.S314923 PMCID: PMC8464303PMID: 34584416 Abstract Acute respiratory syndrome, associated with coronavirus 2 (SARS-CoV-2), is the most important medical and epidemic problem of today. The biggest challenge is to find an effective treatment and to reduce […]

Doctor’s Checklist for Treating Long COVID Patients

Written by Hallie Levine April 4, 2023 Lisa McCorkell had a mild bout of COVID-19 in March 2020. Young and healthy, she assumed that she would bounce back quickly. But when her fatigue, shortness of breath, and brain fog persisted, she realized that she most likely had long COVID.  “Back then, we as patients basically coined […]

How Covid-19 damages lungs explained

Authors: mINT oCTOBER 31, 2022 sYNOPSIS SARS-CoV-2 is the third novel coronavirus to cause human outbreaks in the 21st century, following SARS-CoV in 2003 and MERS-CoV in 2012. Covid-19: The virus attacks mitochondria, continuing an ancient battle that began in the primordial soup Kingston (Canada), (The Conversation): Viruses and bacteria have a very long history. […]

Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19

Authors: Denise Battaglini, 1 , 2 , 3 Miquéias Lopes-Pacheco, 4 Hugo C. Castro-Faria-Neto, 5 Paolo Pelosi, 1 , 2 and Patricia R. M. Rocco 4 , 6 , 7 , * Front Immunol. 2022; 13: 857573.  Apr 27.  2022 doi: 10.3389/fimmu.2022.857573 PMCID: PMC9091347 PMID: 35572561 Abstract Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) causes a wide spectrum of clinical manifestations, with progression to multiorgan failure in the most severe cases. Several biomarkers can be altered […]

Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people

Julia Hippisley-Cox1, Duncan Young2,3, Carol Coupland4, Keith M Channon5, Pui San Tan6, David A Harrison7, Kathryn Rowan8,  Paul Aveyard6, Ian D Pavord9, Peter J Watkinson5,10 Correspondence to Prof Julia Hippisley-Cox, Primary Care Health Sciences, University of Oxford, Oxford OX1  Abstract Background  There is uncertainty about the associations of angiotensive enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) drugs with COVID-19 disease. We studied whether […]